Regeneron Pharmaceuticals Inc (REGN)

Return on assets (ROA)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	3,953,600	3,991,100	4,299,000	4,182,700	4,338,400	5,370,300	5,686,800	7,933,600	8,075,300	6,995,500	6,205,400	4,003,800	3,513,200	3,156,000	2,983,500	2,279,300	2,115,800	2,144,200	2,069,300	2,427,600
Total assets	US$ in thousands	33,080,200	32,163,300	30,657,500	30,059,900	29,214,500	27,677,800	27,205,800	26,348,700	25,434,800	23,671,500	21,485,900	17,772,200	17,163,300	16,084,000	14,428,700	15,757,500	14,805,200	13,939,300	13,173,600	12,854,800
ROA		11.95%	12.41%	14.02%	13.91%	14.85%	19.40%	20.90%	30.11%	31.75%	29.55%	28.88%	22.53%	20.47%	19.62%	20.68%	14.46%	14.29%	15.38%	15.71%	18.88%

December 31, 2023 calculation

ROA = Net income (ttm) ÷ Total assets
= $3,953,600K ÷ $33,080,200K
= 11.95%

Regeneron Pharmaceuticals, Inc.'s return on assets (ROA) has shown a declining trend over the past eight quarters. The ROA decreased from 30.11% in Q1 2022 to 11.95% in Q4 2023. This significant decline indicates a decrease in the company's ability to generate earnings relative to its total assets.

The ROA peaked at 30.11% in Q1 2022, suggesting that the company was efficiently utilizing its assets to generate profits. However, the consistent decline in ROA since then may raise concerns about the company's asset management efficiency.

The average ROA over the past eight quarters is approximately 17.89%. A declining trend in ROA could indicate challenges in maintaining profitability or inefficiencies in asset utilization. Further analysis of the company's financial health, operational efficiency, and strategic decisions would be necessary to understand the underlying factors causing the decline in ROA.